RT Journal Article
SR Electronic
T1 Real world costs and barriers to the successful implementation of rectal artesunate as pre-referral treatment for severe malaria in Sub-Saharan Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.24.22275488
DO 10.1101/2022.05.24.22275488
A1 Lambiris, Mark
A1 Ndongala, Guy
A1 Ssempala, Richard
A1 Balogun, Victor
A1 Musiitwa, Michael
A1 Kagwire, Fred
A1 Olosunde, Oluseyi
A1 Emedo, Emmanel
A1 Luketa, Sylvie
A1 Sangare, Moulaye
A1 Buj, Valentina
A1 Delvento, Giulia
A1 Galactionova, Katya
A1 Okitawutshu, Jean
A1 Tshefu, Antoinette
A1 Omoluabi, Elizabeth
A1 Awor, Phyllis
A1 Signorell, Aita
A1 Hetzel, Manuel W.
A1 Lee, Tristan T.
A1 Brunner, Nina C.
A1 Cereghetti, Nadja
A1 Visser, Theodoor
A1 Napier, Harriet G.
A1 Burri, Christian
A1 Lengeler, Christian
YR 2022
UL http://medrxiv.org/content/early/2022/05/27/2022.05.24.22275488.abstract
AB Background Rectal artesunate (RAS), an efficacious pre-referral treatment for severe malaria in children, was deployed at scale in Uganda, Nigeria and DR Congo. In addition to distributing RAS, implementation required additional investments in crucial but neglected components in the care for severe malaria. We examined the real-world costs and barriers to RAS implementation.Methods We collected primary data on baseline health system gaps and subsequent RAS implementation expenditures. We calculated the equivalent annual cost of RAS implementation per child under 5 at risk of severe malaria, from a health system perspective, separating neglected routine health system components from incremental RAS introduction costs.Findings The largest baseline gaps were irregular health worker supervisions, inadequate referral facility worker training, and inadequate malaria commodity supplies. Health worker training and behaviour change campaigns were the largest startup costs, while supervision and supply chain management accounted for most annual routine costs. The equivalent annual costs of preparing the health system for treating severe malaria with RAS were $2.31, $2.20 and 4.15 per child at risk in Uganda, Nigeria and DRC. The incremental costs of introducing RAS, net of routine neglected components, accounted for a minority at $0.72, $0.59 and $0.94.Interpretation While RAS has been touted as a cost-effective pre-referral treatment for severe malaria in children, its real-world potential is limited by weak and under-financed continuums of care. Scaling up RAS or other interventions relying on community healthcare providers only makes sense alongside additional, essential health system investments sustained over the long-term.Funding UnitaidCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by Unitaid.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data may be made available post-publication on agreement of all contributing parties.